Q3 Earnings Forecast for CRNX Issued By Leerink Partnrs

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Leerink Partnrs cut their Q3 2025 EPS estimates for Crinetics Pharmaceuticals in a research report issued on Tuesday, February 4th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($1.14) per share for the quarter, down from their previous estimate of ($1.12). The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.24) EPS and FY2026 earnings at ($4.99) EPS.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same quarter in the prior year, the company posted ($1.01) EPS.

CRNX has been the topic of several other reports. JMP Securities reaffirmed a “market outperform” rating and set a $87.00 price objective on shares of Crinetics Pharmaceuticals in a report on Monday, December 16th. Citigroup upped their price objective on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Wolfe Research initiated coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday. They set a “peer perform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. Finally, Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Crinetics Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $72.64.

Crinetics Pharmaceuticals Stock Down 1.5 %

NASDAQ CRNX opened at $38.71 on Friday. Crinetics Pharmaceuticals has a 52 week low of $35.51 and a 52 week high of $62.53. The firm’s 50-day simple moving average is $47.81 and its two-hundred day simple moving average is $51.89.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Crinetics Pharmaceuticals by 75.5% during the 3rd quarter. Barclays PLC now owns 207,712 shares of the company’s stock valued at $10,614,000 after purchasing an additional 89,358 shares during the period. Franklin Resources Inc. lifted its holdings in Crinetics Pharmaceuticals by 61.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,390,110 shares of the company’s stock worth $73,815,000 after purchasing an additional 528,688 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Crinetics Pharmaceuticals by 10.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company’s stock worth $94,458,000 after purchasing an additional 169,746 shares in the last quarter. Jennison Associates LLC lifted its holdings in Crinetics Pharmaceuticals by 0.5% in the 3rd quarter. Jennison Associates LLC now owns 2,793,614 shares of the company’s stock worth $142,754,000 after purchasing an additional 13,470 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Crinetics Pharmaceuticals by 8.4% during the 3rd quarter. Fisher Asset Management LLC now owns 482,099 shares of the company’s stock worth $24,635,000 after acquiring an additional 37,429 shares in the last quarter. 98.51% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $39.07, for a total value of $195,350.00. Following the completion of the transaction, the insider now owns 31,748 shares of the company’s stock, valued at $1,240,394.36. The trade was a 13.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jeff E. Knight sold 501 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.52, for a total value of $28,316.52. Following the completion of the sale, the chief operating officer now owns 51,653 shares of the company’s stock, valued at $2,919,427.56. The trade was a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.00% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.